[HIV-HCV co-infection: where are we now?].
Hepatitis C virus (HCV) infection remains a major concern in human immunodeficiency virus (HIV) infected people because of its prevalence and clinical consequences. Management of these patients has evolved, becoming more and more demanding on therapeutic goals and means, not only regarding antiretroviral therapy but also anti-HCV therapy. Thus, if the results of current management are encouraging, they nevertheless is insufficient. It underlines the imperative need for a better comprehension of the essential elements of HCV-HIV co-infection natural history and of the determinants of response to HCV therapy, in particular with pivotal studies such as the ANRS HC 02 RIBAVIC trial.
Piroth
L
L
Département d'infectiologie, CHU, Dijon, France. lionel.piroth@chu-dijon.fr
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000998:Antiviral Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015897:Comorbidity; D005602:France / Q000453:epidemiology; D006678:HIV / Q000187:drug effects / Q000472:pathogenicity; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D016174:Hepacivirus / Q000187:drug effects / Q000472:pathogenicity; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D015995:Prevalence; D011379:Prognosis; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use; D012307:Risk Factors; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin; D007372:Interferons